JP6352244B2 - 骨格筋疲労に対する耐性を向上させるための方法 - Google Patents
骨格筋疲労に対する耐性を向上させるための方法 Download PDFInfo
- Publication number
- JP6352244B2 JP6352244B2 JP2015505896A JP2015505896A JP6352244B2 JP 6352244 B2 JP6352244 B2 JP 6352244B2 JP 2015505896 A JP2015505896 A JP 2015505896A JP 2015505896 A JP2015505896 A JP 2015505896A JP 6352244 B2 JP6352244 B2 JP 6352244B2
- Authority
- JP
- Japan
- Prior art keywords
- xii
- alkyl
- imidazo
- pyrazin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000002027 skeletal muscle Anatomy 0.000 title claims description 166
- 206010049565 Muscle fatigue Diseases 0.000 title claims description 51
- 238000000034 method Methods 0.000 title description 77
- -1 1- (2 - ((3-fluoro-1- (3-fluoropyridin-2-yl) cyclobutyl) methyl) pyrimidin-5-yl)-1H-pyrrole Chemical compound 0.000 claims description 252
- 229940125913 troponin activator Drugs 0.000 claims description 99
- 208000030175 lameness Diseases 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 222
- 150000001875 compounds Chemical class 0.000 description 212
- 210000003205 muscle Anatomy 0.000 description 130
- 206010016256 fatigue Diseases 0.000 description 127
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 124
- 125000001424 substituent group Chemical group 0.000 description 115
- 241000700159 Rattus Species 0.000 description 108
- 125000003118 aryl group Chemical group 0.000 description 97
- 229940126062 Compound A Drugs 0.000 description 89
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 89
- 229910052736 halogen Inorganic materials 0.000 description 87
- 150000002367 halogens Chemical class 0.000 description 87
- 229910052799 carbon Inorganic materials 0.000 description 79
- 229910052739 hydrogen Inorganic materials 0.000 description 75
- 239000001257 hydrogen Substances 0.000 description 75
- 239000011575 calcium Substances 0.000 description 69
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 68
- 230000000694 effects Effects 0.000 description 68
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 64
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 58
- 125000001072 heteroaryl group Chemical group 0.000 description 58
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 58
- 210000003371 toe Anatomy 0.000 description 57
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 55
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 54
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 54
- 125000000392 cycloalkenyl group Chemical group 0.000 description 53
- 125000003710 aryl alkyl group Chemical group 0.000 description 49
- 238000012360 testing method Methods 0.000 description 46
- 230000001965 increasing effect Effects 0.000 description 45
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 44
- 150000002431 hydrogen Chemical class 0.000 description 43
- 125000004043 oxo group Chemical group O=* 0.000 description 40
- 125000003342 alkenyl group Chemical group 0.000 description 39
- 125000000753 cycloalkyl group Chemical group 0.000 description 36
- 210000001087 myotubule Anatomy 0.000 description 36
- 102000004903 Troponin Human genes 0.000 description 34
- 108090001027 Troponin Proteins 0.000 description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 31
- 230000000638 stimulation Effects 0.000 description 31
- 238000011282 treatment Methods 0.000 description 31
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 29
- 125000004432 carbon atom Chemical group C* 0.000 description 28
- 125000001624 naphthyl group Chemical group 0.000 description 28
- 125000003545 alkoxy group Chemical group 0.000 description 27
- 238000011065 in-situ storage Methods 0.000 description 27
- 206010019280 Heart failures Diseases 0.000 description 26
- 125000001188 haloalkyl group Chemical group 0.000 description 26
- 239000003981 vehicle Substances 0.000 description 26
- 125000000304 alkynyl group Chemical group 0.000 description 25
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 24
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 24
- 150000001721 carbon Chemical group 0.000 description 23
- 230000007423 decrease Effects 0.000 description 23
- 239000000835 fiber Substances 0.000 description 23
- 230000035945 sensitivity Effects 0.000 description 23
- 125000005842 heteroatom Chemical group 0.000 description 22
- 229910052717 sulfur Chemical group 0.000 description 22
- 239000012190 activator Substances 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 20
- 150000005829 chemical entities Chemical class 0.000 description 20
- 125000005843 halogen group Chemical group 0.000 description 20
- 229910052791 calcium Inorganic materials 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 210000002235 sarcomere Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000004220 muscle function Effects 0.000 description 16
- 229910052731 fluorine Inorganic materials 0.000 description 15
- 239000011737 fluorine Substances 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 14
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 14
- 230000008602 contraction Effects 0.000 description 14
- 230000036470 plasma concentration Effects 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 125000002252 acyl group Chemical group 0.000 description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 125000004076 pyridyl group Chemical group 0.000 description 13
- 230000004913 activation Effects 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 12
- 230000003189 isokinetic effect Effects 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- 239000012453 solvate Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 238000003419 tautomerization reaction Methods 0.000 description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 11
- 238000012549 training Methods 0.000 description 11
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 102000003505 Myosin Human genes 0.000 description 10
- 210000003423 ankle Anatomy 0.000 description 10
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 10
- 125000003367 polycyclic group Chemical group 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 125000000547 substituted alkyl group Chemical group 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 9
- 108060008487 Myosin Proteins 0.000 description 9
- 102000013534 Troponin C Human genes 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 description 8
- 125000006413 ring segment Chemical group 0.000 description 8
- 239000011593 sulfur Chemical group 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000005441 aurora Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 125000002541 furyl group Chemical group 0.000 description 7
- 210000002414 leg Anatomy 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 210000003365 myofibril Anatomy 0.000 description 7
- 125000002971 oxazolyl group Chemical group 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 125000005415 substituted alkoxy group Chemical group 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 125000003831 tetrazolyl group Chemical group 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 125000001425 triazolyl group Chemical group 0.000 description 7
- RSQGZEAXODVTOL-UHFFFAOYSA-N 5-ethynyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical group C#CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 RSQGZEAXODVTOL-UHFFFAOYSA-N 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 6
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229910001424 calcium ion Inorganic materials 0.000 description 6
- 230000001351 cycling effect Effects 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 210000001105 femoral artery Anatomy 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 125000001786 isothiazolyl group Chemical group 0.000 description 6
- 125000000842 isoxazolyl group Chemical group 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000004118 muscle contraction Effects 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 125000001715 oxadiazolyl group Chemical group 0.000 description 6
- 125000005412 pyrazyl group Chemical group 0.000 description 6
- 125000005495 pyridazyl group Chemical group 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- 125000005017 substituted alkenyl group Chemical group 0.000 description 6
- 125000004426 substituted alkynyl group Chemical group 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000002435 tendon Anatomy 0.000 description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 description 6
- 125000000335 thiazolyl group Chemical group 0.000 description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 5
- 101000941277 Rattus norvegicus Endothelial lipase Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 125000005605 benzo group Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002979 radial nerve Anatomy 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- SYUYQEHWWBTQJK-KTROKBFUSA-N 3-[(1s)-1-phenylethyl]-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)/C=C/C)=CC=CC=C1 SYUYQEHWWBTQJK-KTROKBFUSA-N 0.000 description 4
- TUPQQYNBJJLKFQ-UHFFFAOYSA-N 3-pentan-3-yl-5-(trifluoromethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound FC(F)(F)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 TUPQQYNBJJLKFQ-UHFFFAOYSA-N 0.000 description 4
- WYRAXYZTIXGPNA-DAXSKMNVSA-N 3-pentan-3-yl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C/C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WYRAXYZTIXGPNA-DAXSKMNVSA-N 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- OOWPKYXJAWXXJL-UHFFFAOYSA-N 5-(dimethylamino)-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(N(C)C)N=C2N(C(CC)CC)C(O)=NC2=N1 OOWPKYXJAWXXJL-UHFFFAOYSA-N 0.000 description 4
- XLKNITFKTUIDMX-UHFFFAOYSA-N 5-bromo-3-(2-methyl-1-morpholin-4-ylpropan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C(C)(C)CN1CCOCC1 XLKNITFKTUIDMX-UHFFFAOYSA-N 0.000 description 4
- JVUXJJNMSWDQNZ-MRVPVSSYSA-N 5-bromo-3-[(2r)-1-morpholin-4-ylpropan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](C)N1C2=NC(Br)=CN=C2N=C1O)N1CCOCC1 JVUXJJNMSWDQNZ-MRVPVSSYSA-N 0.000 description 4
- JCLOPOHRCQTTGK-UHFFFAOYSA-N 5-methoxy-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)N=C2N(C(CC)CC)C(O)=NC2=N1 JCLOPOHRCQTTGK-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 108010030743 Tropomyosin Proteins 0.000 description 4
- 102000005937 Tropomyosin Human genes 0.000 description 4
- 102000013394 Troponin I Human genes 0.000 description 4
- 108010065729 Troponin I Proteins 0.000 description 4
- 102000004987 Troponin T Human genes 0.000 description 4
- 108090001108 Troponin T Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 description 4
- 238000003305 oral gavage Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- ZKELHGFJSAVRCZ-UHFFFAOYSA-N 3-(1-morpholin-4-ylbutan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=CN=C2N1C(CC)CN1CCOCC1 ZKELHGFJSAVRCZ-UHFFFAOYSA-N 0.000 description 3
- WAXQRVPDPGLRKE-QMMMGPOBSA-N 5-bromo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical group C1([C@H](C)N2C(NC3=NC=C(Br)N=C32)=O)=CC=CC=C1 WAXQRVPDPGLRKE-QMMMGPOBSA-N 0.000 description 3
- JMZLLOCPIPPQSP-UHFFFAOYSA-N 5-bromo-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CC)CC)C(O)=NC2=N1 JMZLLOCPIPPQSP-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 229950006137 dexfosfoserine Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 238000010825 rotarod performance test Methods 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- TVYCYSWASMVOMJ-UHFFFAOYSA-N 1,2-dihydropyrazolo[3,4-d][1,3]thiazol-3-one Chemical compound N1=CSC2=C1NNC2=O TVYCYSWASMVOMJ-UHFFFAOYSA-N 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 2
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 2
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 description 2
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 2
- YHNUAFQPACGRHG-UHFFFAOYSA-N 2-(5-bromo-2-oxo-1h-imidazo[4,5-b]pyrazin-3-yl)butanoic acid Chemical compound C1=C(Br)N=C2N(C(C(O)=O)CC)C(O)=NC2=N1 YHNUAFQPACGRHG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- OEKBTLYYLIHXOZ-UHFFFAOYSA-N 2-oxo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 OEKBTLYYLIHXOZ-UHFFFAOYSA-N 0.000 description 2
- UPHGKXBLNGRTEU-VIFPVBQESA-N 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carbonitrile Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C#N)=CC=CC=C1 UPHGKXBLNGRTEU-VIFPVBQESA-N 0.000 description 2
- FAICLJXBBVXJHR-QMMMGPOBSA-N 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(N)=O)=CC=CC=C1 FAICLJXBBVXJHR-QMMMGPOBSA-N 0.000 description 2
- AUEBQUCREPKUBN-QMMMGPOBSA-N 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxylic acid Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(O)=O)=CC=CC=C1 AUEBQUCREPKUBN-QMMMGPOBSA-N 0.000 description 2
- BWMYZRWUZRHUKK-UHFFFAOYSA-N 2-oxo-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazine-5-carbonitrile Chemical compound C1=C(C#N)N=C2N(C(CC)CC)C(O)=NC2=N1 BWMYZRWUZRHUKK-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- LAQJGAKLLZAETL-UHFFFAOYSA-N 2h-pyrazin-3-one Chemical compound O=C1CN=CC=N1 LAQJGAKLLZAETL-UHFFFAOYSA-N 0.000 description 2
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical compound N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 description 2
- OIDUDOFDKDVFTB-UHFFFAOYSA-N 3-(1-aminobutan-2-yl)-5-bromo-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CN)CC)C(O)=NC2=N1 OIDUDOFDKDVFTB-UHFFFAOYSA-N 0.000 description 2
- SSZGBXHOXMJQIV-NSCUHMNNSA-N 3-(oxan-4-yl)-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(/C=C/C)=CN=C2N=C(O)N1C1CCOCC1 SSZGBXHOXMJQIV-NSCUHMNNSA-N 0.000 description 2
- SSZGBXHOXMJQIV-IHWYPQMZSA-N 3-(oxan-4-yl)-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(\C=C/C)=CN=C2NC(=O)N1C1CCOCC1 SSZGBXHOXMJQIV-IHWYPQMZSA-N 0.000 description 2
- GXTJPCRFZLLAQY-VIFPVBQESA-N 3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=CN=C32)=O)=CC=CC=C1 GXTJPCRFZLLAQY-VIFPVBQESA-N 0.000 description 2
- KMPZIANLLDHFPH-NSHDSACASA-N 3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]quinoxalin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC4=CC=CC=C4N=C32)=O)=CC=CC=C1 KMPZIANLLDHFPH-NSHDSACASA-N 0.000 description 2
- FGVNKQWCHAKDRY-AWEZNQCLSA-N 3-[(1s)-1-phenylethyl]-5-(piperidin-1-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(CN4CCCCC4)N=C32)=O)=CC=CC=C1 FGVNKQWCHAKDRY-AWEZNQCLSA-N 0.000 description 2
- SFDROONMRQVZOL-ZDUSSCGKSA-N 3-[(1s)-1-phenylethyl]-5-(piperidine-1-carbonyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C(=O)N2CCCCC2)=O)=CC=CC=C1 SFDROONMRQVZOL-ZDUSSCGKSA-N 0.000 description 2
- SYUYQEHWWBTQJK-UFVHFEBBSA-N 3-[(1s)-1-phenylethyl]-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)\C=C/C)=CC=CC=C1 SYUYQEHWWBTQJK-UFVHFEBBSA-N 0.000 description 2
- HGXDYLNWUSYQKP-NSHDSACASA-N 3-[(1s)-1-phenylethyl]-5-propyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)CCC)=CC=CC=C1 HGXDYLNWUSYQKP-NSHDSACASA-N 0.000 description 2
- FMCGTDCYKPWFQL-UHFFFAOYSA-N 3-benzyl-5-bromo-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1CC1=CC=CC=C1 FMCGTDCYKPWFQL-UHFFFAOYSA-N 0.000 description 2
- GZESQDDXLPQCPD-UHFFFAOYSA-N 3-benzyl-5-methylsulfanyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(SC)=CN=C2NC(=O)N1CC1=CC=CC=C1 GZESQDDXLPQCPD-UHFFFAOYSA-N 0.000 description 2
- NSPIDWPREXAAAQ-QHHAFSJGSA-N 3-cyclohexyl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(/C=C/C)=CN=C2NC(=O)N1C1CCCCC1 NSPIDWPREXAAAQ-QHHAFSJGSA-N 0.000 description 2
- NSPIDWPREXAAAQ-KXFIGUGUSA-N 3-cyclohexyl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(\C=C/C)=CN=C2NC(=O)N1C1CCCCC1 NSPIDWPREXAAAQ-KXFIGUGUSA-N 0.000 description 2
- QTFTVOGPJMOQQQ-UHFFFAOYSA-N 3-cyclohexyl-5-methylsulfanyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(SC)=CN=C2N=C(O)N1C1CCCCC1 QTFTVOGPJMOQQQ-UHFFFAOYSA-N 0.000 description 2
- KUFBAWMESFZISC-NSCUHMNNSA-N 3-cyclopropyl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(/C=C/C)=CN=C2NC(=O)N1C1CC1 KUFBAWMESFZISC-NSCUHMNNSA-N 0.000 description 2
- KUFBAWMESFZISC-IHWYPQMZSA-N 3-cyclopropyl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(\C=C/C)=CN=C2NC(=O)N1C1CC1 KUFBAWMESFZISC-IHWYPQMZSA-N 0.000 description 2
- WJOZHHCMYYPKPL-UHFFFAOYSA-N 3-cyclopropyl-5-methylsulfanyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(SC)=CN=C2NC(=O)N1C1CC1 WJOZHHCMYYPKPL-UHFFFAOYSA-N 0.000 description 2
- LJPNHODRROZMGG-UHFFFAOYSA-N 3-pentan-3-yl-1,4-dihydroimidazo[4,5-b]pyrazine-2,5-dione Chemical compound C1=C(O)N=C2N(C(CC)CC)C(O)=NC2=N1 LJPNHODRROZMGG-UHFFFAOYSA-N 0.000 description 2
- OQTVWLOQVMHOME-UHFFFAOYSA-N 3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 OQTVWLOQVMHOME-UHFFFAOYSA-N 0.000 description 2
- QWIGXPXZXMRYFN-UHFFFAOYSA-N 3-pentan-3-yl-1h-imidazo[4,5-b]quinoxalin-2-one Chemical compound C1=CC=C2N=C(NC(N3C(CC)CC)=O)C3=NC2=C1 QWIGXPXZXMRYFN-UHFFFAOYSA-N 0.000 description 2
- WSZAYYDHFCRVMT-UHFFFAOYSA-N 3-pentan-3-yl-5-(2h-triazol-4-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(C(CC)CC)C2=NC=1C1=CNN=N1 WSZAYYDHFCRVMT-UHFFFAOYSA-N 0.000 description 2
- WYRAXYZTIXGPNA-QPJJXVBHSA-N 3-pentan-3-yl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C/C=C/C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WYRAXYZTIXGPNA-QPJJXVBHSA-N 0.000 description 2
- ZUKQRELSXSZGNR-UHFFFAOYSA-N 3-pentan-3-yl-5-prop-1-en-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC(=C)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 ZUKQRELSXSZGNR-UHFFFAOYSA-N 0.000 description 2
- RKWUIYMGQOAXEZ-UHFFFAOYSA-N 3-pentan-3-yl-5-prop-1-ynyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC#CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 RKWUIYMGQOAXEZ-UHFFFAOYSA-N 0.000 description 2
- LQLUETZNTCJOCT-UHFFFAOYSA-N 3-pentan-3-yl-5-propan-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC(C)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 LQLUETZNTCJOCT-UHFFFAOYSA-N 0.000 description 2
- PFKZWBXZBQPWJI-SNAWJCMRSA-N 3-propan-2-yl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C\C1=CN=C2NC(=O)N(C(C)C)C2=N1 PFKZWBXZBQPWJI-SNAWJCMRSA-N 0.000 description 2
- PFKZWBXZBQPWJI-PLNGDYQASA-N 3-propan-2-yl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C/C1=CN=C2N=C(O)N(C(C)C)C2=N1 PFKZWBXZBQPWJI-PLNGDYQASA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- WGJUBVJZKNTGRC-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Chemical compound N1=CN=C2CNCCC2=C1 WGJUBVJZKNTGRC-UHFFFAOYSA-N 0.000 description 2
- UEPSYMITWMMTTJ-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(C(CC)CC)C2=NC=1C=1C=NN(C)C=1 UEPSYMITWMMTTJ-UHFFFAOYSA-N 0.000 description 2
- DXQMTYNFSGEMLQ-JTQLQIEISA-N 5-(2-hydroxypropan-2-yl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C(C)(C)O)=O)=CC=CC=C1 DXQMTYNFSGEMLQ-JTQLQIEISA-N 0.000 description 2
- JPWVZDIMURSFIS-LBPRGKRZSA-N 5-(2-methylprop-1-enyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(C=C(C)C)N=C32)=O)=CC=CC=C1 JPWVZDIMURSFIS-LBPRGKRZSA-N 0.000 description 2
- NYEFRVNUSQHDBP-LBPRGKRZSA-N 5-(2-methylpropyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)CC(C)C)=CC=CC=C1 NYEFRVNUSQHDBP-LBPRGKRZSA-N 0.000 description 2
- BYVOWOPGLJOQGT-ZDUSSCGKSA-N 5-(4-methylpiperazine-1-carbonyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(=O)N2CCN(C)CC2)=CC=CC=C1 BYVOWOPGLJOQGT-ZDUSSCGKSA-N 0.000 description 2
- SUQDOUCHWLHPQX-ZDUSSCGKSA-N 5-(cyclohexen-1-yl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C=2CCCCC=2)=O)=CC=CC=C1 SUQDOUCHWLHPQX-ZDUSSCGKSA-N 0.000 description 2
- KCDSJTGZFUDLON-ZDUSSCGKSA-N 5-(morpholin-4-ylmethyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(CN4CCOCC4)N=C32)=O)=CC=CC=C1 KCDSJTGZFUDLON-ZDUSSCGKSA-N 0.000 description 2
- SFPQZTPFSOQKEW-LBPRGKRZSA-N 5-(morpholine-4-carbonyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(=O)N2CCOCC2)=CC=CC=C1 SFPQZTPFSOQKEW-LBPRGKRZSA-N 0.000 description 2
- RIUFVPWKDKPVEE-AWEZNQCLSA-N 5-[(4-methylpiperazin-1-yl)methyl]-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(CN4CCN(C)CC4)N=C32)=O)=CC=CC=C1 RIUFVPWKDKPVEE-AWEZNQCLSA-N 0.000 description 2
- LNSUVMJIGLAFPI-NSHDSACASA-N 5-[(dimethylamino)methyl]-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(CN(C)C)N=C32)=O)=CC=CC=C1 LNSUVMJIGLAFPI-NSHDSACASA-N 0.000 description 2
- KXFYDWMMZNBTKB-UQYHUFHVSA-N 5-[(z)-hex-2-enyl]-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)C\C=C/CCC)=CC=CC=C1 KXFYDWMMZNBTKB-UQYHUFHVSA-N 0.000 description 2
- ATHOGNKKHWAYKT-UHFFFAOYSA-N 5-acetyl-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 ATHOGNKKHWAYKT-UHFFFAOYSA-N 0.000 description 2
- NMFBGMYSYPALNO-UHFFFAOYSA-N 5-bromo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2NC(=O)N(C(CC)CC)C2=N1 NMFBGMYSYPALNO-UHFFFAOYSA-N 0.000 description 2
- HYRCCFZTXSFHMB-UHFFFAOYSA-N 5-bromo-3-(1,3-dihydroxypropan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CO)CO)C(O)=NC2=N1 HYRCCFZTXSFHMB-UHFFFAOYSA-N 0.000 description 2
- XPHYYSKGOGGPLD-UHFFFAOYSA-N 5-bromo-3-(1-methoxybutan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N(C(COC)CC)C2=N1 XPHYYSKGOGGPLD-UHFFFAOYSA-N 0.000 description 2
- UHVXLYLFBCPIBH-UHFFFAOYSA-N 5-bromo-3-(1-morpholin-4-yl-1-oxobutan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C(CC)C(=O)N1CCOCC1 UHVXLYLFBCPIBH-UHFFFAOYSA-N 0.000 description 2
- BKRHNTRJIUKUOI-UHFFFAOYSA-N 5-bromo-3-(2-morpholin-4-ylethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1CCN1CCOCC1 BKRHNTRJIUKUOI-UHFFFAOYSA-N 0.000 description 2
- QFFFSTQFQPYCHG-UHFFFAOYSA-N 5-bromo-3-(oxan-4-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C1CCOCC1 QFFFSTQFQPYCHG-UHFFFAOYSA-N 0.000 description 2
- WAXQRVPDPGLRKE-MRVPVSSYSA-N 5-bromo-3-[(1r)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@@H](C)N2C3=NC(Br)=CN=C3N=C2O)=CC=CC=C1 WAXQRVPDPGLRKE-MRVPVSSYSA-N 0.000 description 2
- HRHMIFIUUCUENC-RXMQYKEDSA-N 5-bromo-3-[(2r)-1-hydroxybutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N([C@@H](CO)CC)C(O)=NC2=N1 HRHMIFIUUCUENC-RXMQYKEDSA-N 0.000 description 2
- YQOCSKOMOMCTOF-SECBINFHSA-N 5-bromo-3-[(2r)-1-morpholin-4-ylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](CC)N1C2=NC(Br)=CN=C2N=C1O)N1CCOCC1 YQOCSKOMOMCTOF-SECBINFHSA-N 0.000 description 2
- HJHNPXSPMAXXDO-LLVKDONJSA-N 5-bromo-3-[(2r)-4-methyl-1-morpholin-4-ylpentan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](CC(C)C)N1C2=NC(Br)=CN=C2N=C1O)N1CCOCC1 HJHNPXSPMAXXDO-LLVKDONJSA-N 0.000 description 2
- UMUXBNQISPBMHB-RXMQYKEDSA-N 5-bromo-3-[(2r)-butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N([C@H](C)CC)C2=N1 UMUXBNQISPBMHB-RXMQYKEDSA-N 0.000 description 2
- HRHMIFIUUCUENC-YFKPBYRVSA-N 5-bromo-3-[(2s)-1-hydroxybutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N([C@H](CO)CC)C2=N1 HRHMIFIUUCUENC-YFKPBYRVSA-N 0.000 description 2
- JVUXJJNMSWDQNZ-QMMMGPOBSA-N 5-bromo-3-[(2s)-1-morpholin-4-ylpropan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@H](C)N1C2=NC(Br)=CN=C2N=C1O)N1CCOCC1 JVUXJJNMSWDQNZ-QMMMGPOBSA-N 0.000 description 2
- UMUXBNQISPBMHB-YFKPBYRVSA-N 5-bromo-3-[(2s)-butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N([C@@H](C)CC)C2=N1 UMUXBNQISPBMHB-YFKPBYRVSA-N 0.000 description 2
- DZHHDFNQNKJYQE-UHFFFAOYSA-N 5-bromo-3-[1-(4-methylpiperazin-1-yl)butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C(CC)CN1CCN(C)CC1 DZHHDFNQNKJYQE-UHFFFAOYSA-N 0.000 description 2
- AOLADPNSDQMWQF-UHFFFAOYSA-N 5-bromo-3-[1-(4-methylsulfonylpiperazin-1-yl)butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1C(CC)CN1CCN(S(C)(=O)=O)CC1 AOLADPNSDQMWQF-UHFFFAOYSA-N 0.000 description 2
- WDAYLXAGMDBEDY-UHFFFAOYSA-N 5-bromo-3-[1-(dimethylamino)butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CN(C)C)CC)C(O)=NC2=N1 WDAYLXAGMDBEDY-UHFFFAOYSA-N 0.000 description 2
- CIEPWXIBLAGYFB-UHFFFAOYSA-N 5-bromo-3-[1-(methylamino)butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N(C(CNC)CC)C2=N1 CIEPWXIBLAGYFB-UHFFFAOYSA-N 0.000 description 2
- ZTHFIYXLZKQTIZ-UHFFFAOYSA-N 5-bromo-3-cyclohexyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1C1CCCCC1 ZTHFIYXLZKQTIZ-UHFFFAOYSA-N 0.000 description 2
- QZFCGAULXPKETL-UHFFFAOYSA-N 5-bromo-3-cyclopropyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1C1CC1 QZFCGAULXPKETL-UHFFFAOYSA-N 0.000 description 2
- DLGLLQCQYOSWFA-UHFFFAOYSA-N 5-bromo-3-heptan-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CCC)CCC)C(O)=NC2=N1 DLGLLQCQYOSWFA-UHFFFAOYSA-N 0.000 description 2
- RAGKXJIFFMBPQH-UHFFFAOYSA-N 5-bromo-3-propan-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N(C(C)C)C2=N1 RAGKXJIFFMBPQH-UHFFFAOYSA-N 0.000 description 2
- SCOUYZQKEZNSSB-UHFFFAOYSA-N 5-bromo-3-tert-butyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N(C(C)(C)C)C2=N1 SCOUYZQKEZNSSB-UHFFFAOYSA-N 0.000 description 2
- WPDKEIHMTHBWTQ-UHFFFAOYSA-N 5-chloro-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound ClC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WPDKEIHMTHBWTQ-UHFFFAOYSA-N 0.000 description 2
- BFUPGUDOZHKGRY-ZDUSSCGKSA-N 5-cyclohexyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C2CCCCC2)=O)=CC=CC=C1 BFUPGUDOZHKGRY-ZDUSSCGKSA-N 0.000 description 2
- BQHUECBTWVGPTM-UHFFFAOYSA-N 5-cyclopropyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(C(CC)CC)C2=NC=1C1CC1 BQHUECBTWVGPTM-UHFFFAOYSA-N 0.000 description 2
- MTWIPZQQMOGYOA-UHFFFAOYSA-N 5-ethenyl-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(C=C)N=C2NC(=O)N(C(CC)CC)C2=N1 MTWIPZQQMOGYOA-UHFFFAOYSA-N 0.000 description 2
- NDZAPLNYXZLOQS-JTQLQIEISA-N 5-ethenyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(C=C)N=C32)=O)=CC=CC=C1 NDZAPLNYXZLOQS-JTQLQIEISA-N 0.000 description 2
- SBJUQVUTJXSWQG-UHFFFAOYSA-N 5-ethenyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 SBJUQVUTJXSWQG-UHFFFAOYSA-N 0.000 description 2
- AMMCGDYTUNTXNL-JTQLQIEISA-N 5-ethoxy-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)OCC)=CC=CC=C1 AMMCGDYTUNTXNL-JTQLQIEISA-N 0.000 description 2
- BARVETZCMYVZCX-UHFFFAOYSA-N 5-ethyl-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound CCC1=CN=C2N(C(CC)CC)C(O)=NC2=N1 BARVETZCMYVZCX-UHFFFAOYSA-N 0.000 description 2
- KIXVDSJCGANIHE-JTQLQIEISA-N 5-ethyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)CC)=CC=CC=C1 KIXVDSJCGANIHE-JTQLQIEISA-N 0.000 description 2
- JPDFKESEFQRCBE-UHFFFAOYSA-N 5-ethyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CCC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 JPDFKESEFQRCBE-UHFFFAOYSA-N 0.000 description 2
- GMOWAKFCILZILA-GFCCVEGCSA-N 5-ethynyl-3-[(2r)-1-morpholin-4-ylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](CC)N1C2=NC(=CN=C2N=C1O)C#C)N1CCOCC1 GMOWAKFCILZILA-GFCCVEGCSA-N 0.000 description 2
- HQJKFIVXLPPXQC-AWEZNQCLSA-N 5-hexyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)CCCCCC)=CC=CC=C1 HQJKFIVXLPPXQC-AWEZNQCLSA-N 0.000 description 2
- POBMWJBUNZNVBG-VIFPVBQESA-N 5-methoxy-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)OC)=CC=CC=C1 POBMWJBUNZNVBG-VIFPVBQESA-N 0.000 description 2
- UQASQCGBIPPBLD-UHFFFAOYSA-N 5-methyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(C)N=C2N(C(CC)CC)C(O)=NC2=N1 UQASQCGBIPPBLD-UHFFFAOYSA-N 0.000 description 2
- AUOSLRIENXAMHD-UHFFFAOYSA-N 5-methylsulfanyl-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound CSC1=CN=C2N(C(CC)CC)C(O)=NC2=N1 AUOSLRIENXAMHD-UHFFFAOYSA-N 0.000 description 2
- JIEZRCLDDSWWHV-SECBINFHSA-N 5-methylsulfanyl-3-[(1r)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@@H](C)N2C(O)=NC3=NC=C(N=C32)SC)=CC=CC=C1 JIEZRCLDDSWWHV-SECBINFHSA-N 0.000 description 2
- JIEZRCLDDSWWHV-VIFPVBQESA-N 5-methylsulfanyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)SC)=CC=CC=C1 JIEZRCLDDSWWHV-VIFPVBQESA-N 0.000 description 2
- RCBUJATVMKPIKN-UHFFFAOYSA-N 5-methylsulfanyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CSC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 RCBUJATVMKPIKN-UHFFFAOYSA-N 0.000 description 2
- OWUGKZDHFBKQTR-UHFFFAOYSA-N 5-methylsulfanyl-3-propan-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CSC1=CN=C2N=C(O)N(C(C)C)C2=N1 OWUGKZDHFBKQTR-UHFFFAOYSA-N 0.000 description 2
- HFHWCPSMUHVXBR-VIFPVBQESA-N 5-methylsulfonyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)S(C)(=O)=O)=CC=CC=C1 HFHWCPSMUHVXBR-VIFPVBQESA-N 0.000 description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000584208 Homo sapiens Myosin light chain kinase 2, skeletal/cardiac muscle Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101000941278 Mus musculus Endothelial lipase Proteins 0.000 description 2
- 102100030788 Myosin light chain kinase 2, skeletal/cardiac muscle Human genes 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940083712 aldosterone antagonist Drugs 0.000 description 2
- 239000002170 aldosterone antagonist Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000008828 contractile function Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229960001987 dantrolene Drugs 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical group C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000010988 intraclass correlation coefficient Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- ZEDPIMIYEJBDRX-UHFFFAOYSA-N methyl 2-oxo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazine-5-carboxylate Chemical compound COC(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 ZEDPIMIYEJBDRX-UHFFFAOYSA-N 0.000 description 2
- WIDYWXVZKVHDEZ-VIFPVBQESA-N methyl 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxylate Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)C(=O)OC)=CC=CC=C1 WIDYWXVZKVHDEZ-VIFPVBQESA-N 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- CFWJGEAWUINBDG-LBPRGKRZSA-N n,n-diethyl-2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)C(=O)N(CC)CC)=CC=CC=C1 CFWJGEAWUINBDG-LBPRGKRZSA-N 0.000 description 2
- KCSLBARCQXBZTN-UHFFFAOYSA-N n,n-dimethyl-2-oxo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound CN(C)C(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 KCSLBARCQXBZTN-UHFFFAOYSA-N 0.000 description 2
- WFUAIWYQPBEHLA-JTQLQIEISA-N n,n-dimethyl-2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(=O)N(C)C)=CC=CC=C1 WFUAIWYQPBEHLA-JTQLQIEISA-N 0.000 description 2
- SKZMEPYTEPEEQK-AWEZNQCLSA-N n-benzyl-2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(=O)NCC=2C=CC=CC=2)=CC=CC=C1 SKZMEPYTEPEEQK-AWEZNQCLSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- NAPPLGJAEMHOAG-UHFFFAOYSA-N n-methyl-2-oxo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound CNC(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 NAPPLGJAEMHOAG-UHFFFAOYSA-N 0.000 description 2
- QYQZBGDQEVAJKO-VIFPVBQESA-N n-methyl-2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)C(=O)NC)=CC=CC=C1 QYQZBGDQEVAJKO-VIFPVBQESA-N 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 210000000715 neuromuscular junction Anatomy 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000012232 skeletal muscle contraction Effects 0.000 description 2
- 238000013223 sprague-dawley female rat Methods 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 2
- 229960005001 ticlopidine Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SWEICGMKXPNXNU-UHFFFAOYSA-N 1,2-dihydroindazol-3-one Chemical compound C1=CC=C2C(O)=NNC2=C1 SWEICGMKXPNXNU-UHFFFAOYSA-N 0.000 description 1
- FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical compound OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- HUCXRCCJHDFVCI-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-c]pyridin-2-one Chemical compound C1=NC=C2NC(=O)CC2=C1 HUCXRCCJHDFVCI-UHFFFAOYSA-N 0.000 description 1
- IHRRHTILSRVFPW-UHFFFAOYSA-N 1,3-dihydropyrrolo[3,2-b]pyridin-2-one Chemical compound C1=CC=C2NC(=O)CC2=N1 IHRRHTILSRVFPW-UHFFFAOYSA-N 0.000 description 1
- YAUVSURSWJMKFT-UHFFFAOYSA-N 1,3-dihydropyrrolo[3,2-c]pyridin-2-one Chemical compound N1=CC=C2NC(=O)CC2=C1 YAUVSURSWJMKFT-UHFFFAOYSA-N 0.000 description 1
- ABJFBJGGLJVMAQ-UHFFFAOYSA-N 1,4-dihydroquinoxaline-2,3-dione Chemical compound C1=CC=C2NC(=O)C(=O)NC2=C1 ABJFBJGGLJVMAQ-UHFFFAOYSA-N 0.000 description 1
- ADUPQRNIROZRKO-SSDOTTSWSA-N 1-[(2r)-butan-2-yl]-6-chloro-7-(1h-pyrazol-5-yl)-3h-imidazo[4,5-b]pyridin-2-one Chemical compound C=12N([C@H](C)CC)C(O)=NC2=NC=C(Cl)C=1C=1C=CNN=1 ADUPQRNIROZRKO-SSDOTTSWSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical compound N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 1
- FUAXXVSVFLEVSF-UHFFFAOYSA-N 1h-2,1-benzoxazol-3-one Chemical compound C1=CC=C2C(=O)ONC2=C1 FUAXXVSVFLEVSF-UHFFFAOYSA-N 0.000 description 1
- LTFBFZBWUKWXID-UHFFFAOYSA-N 1h-cyclopenta[d]pyrimidine Chemical compound N1=CNC2=CC=CC2=C1 LTFBFZBWUKWXID-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- SSZWKKQDZMVWCW-UHFFFAOYSA-N 3,5,6-trimethyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C(C)C(C)=NC2=C1N(C)C(=O)N2 SSZWKKQDZMVWCW-UHFFFAOYSA-N 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- DGXUBNJTSDKMNH-UHFFFAOYSA-N 3-[2-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyrimidin-5-yl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2C=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=NC=2)=C1 DGXUBNJTSDKMNH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- VGMPXCLEQITWTP-UHFFFAOYSA-N 3-methyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CN=C2NC(=O)N(C)C2=N1 VGMPXCLEQITWTP-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 description 1
- ACZGCWSMSTYWDQ-UHFFFAOYSA-N 3h-1-benzofuran-2-one Chemical compound C1=CC=C2OC(=O)CC2=C1 ACZGCWSMSTYWDQ-UHFFFAOYSA-N 0.000 description 1
- ARTAFUJPRUWRJK-UHFFFAOYSA-N 3h-1-benzothiophen-2-one Chemical compound C1=CC=C2SC(=O)CC2=C1 ARTAFUJPRUWRJK-UHFFFAOYSA-N 0.000 description 1
- NSSBUSDEHNCUIY-UHFFFAOYSA-N 3h-2-benzothiophen-1-one Chemical compound C1=CC=C2C(=O)SCC2=C1 NSSBUSDEHNCUIY-UHFFFAOYSA-N 0.000 description 1
- SLGVJLNVPYQNNK-UHFFFAOYSA-N 3h-cinnolin-4-one Chemical compound C1=CC=C2C(=O)CN=NC2=C1 SLGVJLNVPYQNNK-UHFFFAOYSA-N 0.000 description 1
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 description 1
- BCRHMAZIUFJNEM-UHFFFAOYSA-N 4,5-dihydropyrrolo[3,4-d][1,3]thiazol-6-one Chemical compound N1=CSC2=C1CNC2=O BCRHMAZIUFJNEM-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
- RKYBOAKGTWOIFJ-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine Chemical compound C1=NC=C2CCCNC2=N1 RKYBOAKGTWOIFJ-UHFFFAOYSA-N 0.000 description 1
- VRUDHVVJIWFTGM-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[3,2-d]pyrimidine Chemical compound N1=CN=C2CCCNC2=C1 VRUDHVVJIWFTGM-UHFFFAOYSA-N 0.000 description 1
- STXKJIIHKFGUCY-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine Chemical compound C1=NC=C2CNCCC2=N1 STXKJIIHKFGUCY-UHFFFAOYSA-N 0.000 description 1
- SMSHIXOEBWOYJS-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinazoline Chemical compound C1=NC=C2CCCCC2=N1 SMSHIXOEBWOYJS-UHFFFAOYSA-N 0.000 description 1
- XGYMKEPKOZVQSB-UHFFFAOYSA-N 5-(hydroxymethyl)-1,6-dimethyl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C(CO)C(C)=NC2=C1NC(=O)N2C XGYMKEPKOZVQSB-UHFFFAOYSA-N 0.000 description 1
- QZCBPABKXFZXCW-UHFFFAOYSA-N 5-[2-(2-oxo-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-5-yl)ethynyl]-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2NC(=O)N(C(CC)CC)C2=NC(C#CC2=CN=C3N=C(O)N(C3=N2)C(CC)CC)=C1 QZCBPABKXFZXCW-UHFFFAOYSA-N 0.000 description 1
- LCZJTRRQEFNMEF-VIFPVBQESA-N 5-acetyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(C)=O)=CC=CC=C1 LCZJTRRQEFNMEF-VIFPVBQESA-N 0.000 description 1
- YQOCSKOMOMCTOF-VIFPVBQESA-N 5-bromo-3-[(2s)-1-morpholin-4-ylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@H](CC)N1C(NC2=NC=C(Br)N=C21)=O)N1CCOCC1 YQOCSKOMOMCTOF-VIFPVBQESA-N 0.000 description 1
- QUCSBNPOJMPNDS-UHFFFAOYSA-N 5-bromo-3-[(3-nitrophenyl)methyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound [O-][N+](=O)C1=CC=CC(CN2C(NC3=NC=C(Br)N=C32)=O)=C1 QUCSBNPOJMPNDS-UHFFFAOYSA-N 0.000 description 1
- HDJDBIXLNJULNY-UHFFFAOYSA-N 5-methylsulfanyl-3-(oxan-4-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(SC)=CN=C2NC(=O)N1C1CCOCC1 HDJDBIXLNJULNY-UHFFFAOYSA-N 0.000 description 1
- CXKKSQOGGIFLNS-BZEUWDEWSA-N 5-methylsulfinyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)S(C)=O)=O)=CC=CC=C1 CXKKSQOGGIFLNS-BZEUWDEWSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- PANGDCFLXUDHDI-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NCCC2=C1 PANGDCFLXUDHDI-UHFFFAOYSA-N 0.000 description 1
- LMAYDNVIKBCSLP-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NCCC2=N1 LMAYDNVIKBCSLP-UHFFFAOYSA-N 0.000 description 1
- NBXIOQTYZWAAEB-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[3,4-d]pyrimidine Chemical compound C1=NC=C2CNCC2=N1 NBXIOQTYZWAAEB-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 1
- 239000005485 Azilsartan Substances 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000588969 Homo sapiens Putative uncharacterized protein MYH16 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108030001204 Myosin ATPases Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100032974 Putative uncharacterized protein MYH16 Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 102100027697 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Human genes 0.000 description 1
- 101710109122 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Proteins 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YWBULOYFCXZCGF-UHFFFAOYSA-N [1,3]thiazolo[4,5-d]pyrimidine Chemical compound C1=NC=C2SC=NC2=N1 YWBULOYFCXZCGF-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical compound NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229950004646 azelnidipine Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
- 229960002731 azilsartan Drugs 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- DMSMPAJRVJJAGA-UHFFFAOYSA-N benzo[d]isothiazol-3-one Chemical compound C1=CC=C2C(=O)NSC2=C1 DMSMPAJRVJJAGA-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- VIQRCOQXIHFJND-UHFFFAOYSA-N bicyclo[2.2.2]oct-2-ene Chemical compound C1CC2CCC1C=C2 VIQRCOQXIHFJND-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005510 but-1-en-2-yl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 229960005057 canrenone Drugs 0.000 description 1
- UJVLDDZCTMKXJK-WNHSNXHDSA-N canrenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3C=C2)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 UJVLDDZCTMKXJK-WNHSNXHDSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbamic acid group Chemical group C(N)(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 229960003597 clevidipine Drugs 0.000 description 1
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 1
- 230000002493 climbing effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000000668 effect on calcium Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003114 inden-1-yl group Chemical group [H]C1=C([H])C([H])(*)C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000000111 isothermal titration calorimetry Methods 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960004294 lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- ADZYJDJNIBFOQE-RGKMBJPFSA-N mexrenone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 ADZYJDJNIBFOQE-RGKMBJPFSA-N 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- TUNARGMXIPKYIE-UHFFFAOYSA-N n-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]pyrimidin-2-amine Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=NC=CC=N1 TUNARGMXIPKYIE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000010248 power generation Methods 0.000 description 1
- 229950004891 pranidipine Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- RRHHMFQGHCFGMH-LAPLKBAYSA-N prorenone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3[C@H]3C[C@H]32)C)CC[C@@]11C)C[C@@]11CCC(=O)O1 RRHHMFQGHCFGMH-LAPLKBAYSA-N 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- PLZDHJUUEGCXJH-UHFFFAOYSA-N pyrido[4,3-d]pyrimidine Chemical compound C1=NC=C2C=NC=CC2=N1 PLZDHJUUEGCXJH-UHFFFAOYSA-N 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical compound C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- MQXWPWOCXGARRK-UHFFFAOYSA-N reldesemtiv Chemical compound C1=C(C(=O)N)C=CN1C(C=N1)=CN=C1NCC1(C=2C(=CC=CN=2)F)CC(F)C1 MQXWPWOCXGARRK-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000003875 slow muscle fiber Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005650 substituted phenylene group Chemical group 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- UPCXAARSWVHVLY-UHFFFAOYSA-N tris(2-hydroxyethyl)azanium;acetate Chemical compound CC(O)=O.OCCN(CCO)CCO UPCXAARSWVHVLY-UHFFFAOYSA-N 0.000 description 1
- 108010013477 troponin-tropomyosin complex Proteins 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 229960001844 tubocurarine Drugs 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623003P | 2012-04-11 | 2012-04-11 | |
| US61/623,003 | 2012-04-11 | ||
| US201261646842P | 2012-05-14 | 2012-05-14 | |
| US61/646,842 | 2012-05-14 | ||
| US201261693061P | 2012-08-24 | 2012-08-24 | |
| US61/693,061 | 2012-08-24 | ||
| US201261735809P | 2012-12-11 | 2012-12-11 | |
| US61/735,809 | 2012-12-11 | ||
| PCT/US2013/036114 WO2013155262A2 (en) | 2012-04-11 | 2013-04-11 | Methods for improving resistance to skeletal muscle fatigue |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253312A Division JP6535727B2 (ja) | 2012-04-11 | 2017-12-28 | 骨格筋疲労に対する耐性を向上させるための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516392A JP2015516392A (ja) | 2015-06-11 |
| JP2015516392A5 JP2015516392A5 (https=) | 2016-06-09 |
| JP6352244B2 true JP6352244B2 (ja) | 2018-07-04 |
Family
ID=49328282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505896A Expired - Fee Related JP6352244B2 (ja) | 2012-04-11 | 2013-04-11 | 骨格筋疲労に対する耐性を向上させるための方法 |
| JP2017253312A Expired - Fee Related JP6535727B2 (ja) | 2012-04-11 | 2017-12-28 | 骨格筋疲労に対する耐性を向上させるための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253312A Expired - Fee Related JP6535727B2 (ja) | 2012-04-11 | 2017-12-28 | 骨格筋疲労に対する耐性を向上させるための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150250784A1 (https=) |
| EP (1) | EP2836590A4 (https=) |
| JP (2) | JP6352244B2 (https=) |
| KR (1) | KR102163931B1 (https=) |
| CN (2) | CN111840294A (https=) |
| AU (3) | AU2013245917A1 (https=) |
| BR (1) | BR112014025251B1 (https=) |
| CA (1) | CA2869675C (https=) |
| EA (1) | EA032480B1 (https=) |
| HK (1) | HK1206389A1 (https=) |
| IL (2) | IL234886A (https=) |
| MX (1) | MX2014012179A (https=) |
| PH (1) | PH12014502286B1 (https=) |
| SG (2) | SG11201406359TA (https=) |
| WO (1) | WO2013155262A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| KR101951220B1 (ko) | 2011-07-13 | 2019-02-22 | 싸이토키네틱스, 인코포레이티드 | 조합 als 치료법 |
| EP2970240B1 (en) | 2013-03-14 | 2018-01-10 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| HUE057533T2 (hu) * | 2014-04-29 | 2022-05-28 | Cytokinetics Inc | Eljárások vitálkapacitás csökkenésének gátlására |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
| JP6573618B2 (ja) * | 2014-09-09 | 2019-09-11 | アステラス製薬株式会社 | 尿失禁予防用及び／又は治療用新規医薬組成物 |
| BR112018016475A2 (en) | 2016-02-12 | 2018-12-26 | Cytokinetics, Incorporated | tetrahydroisoquinoline derivatives |
| EP3484876A1 (en) | 2016-07-14 | 2019-05-22 | Pfizer Inc | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| KR20220038056A (ko) | 2019-07-23 | 2022-03-25 | 아모피컬 리미티드 | 운동 수행능력을 개선시키기 위한 비정질 탄산칼슘 |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| WO2022099011A1 (en) | 2020-11-06 | 2022-05-12 | Cytokinetics, Inc. | Bicyclic 1,4-diazepanones and therapeutic uses thereof |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| IL316201A (en) | 2022-04-08 | 2024-12-01 | Eikonizo Therapeutics Inc | Oxadiazole HDAC6 inhibitors and their uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005139081A (ja) * | 2003-11-04 | 2005-06-02 | Takada Seiyaku Kk | ビントペロール含有製剤 |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| CN101522681B (zh) * | 2006-08-02 | 2012-10-03 | 赛特凯恩蒂克公司 | 特定的化学个体、组合物和方法 |
| EP2244711A4 (en) * | 2008-02-04 | 2011-08-24 | Cytokinetics Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| SG10201701101YA (en) * | 2012-04-02 | 2017-04-27 | Cytokinetics Inc | Methods for improving diaphragm function |
-
2013
- 2013-04-11 CN CN202010369880.5A patent/CN111840294A/zh active Pending
- 2013-04-11 MX MX2014012179A patent/MX2014012179A/es unknown
- 2013-04-11 US US14/391,087 patent/US20150250784A1/en not_active Abandoned
- 2013-04-11 KR KR1020147028128A patent/KR102163931B1/ko not_active Expired - Fee Related
- 2013-04-11 WO PCT/US2013/036114 patent/WO2013155262A2/en not_active Ceased
- 2013-04-11 SG SG11201406359TA patent/SG11201406359TA/en unknown
- 2013-04-11 SG SG10201704166RA patent/SG10201704166RA/en unknown
- 2013-04-11 CN CN201380019567.7A patent/CN104395458A/zh active Pending
- 2013-04-11 HK HK15106995.5A patent/HK1206389A1/xx unknown
- 2013-04-11 JP JP2015505896A patent/JP6352244B2/ja not_active Expired - Fee Related
- 2013-04-11 EP EP13775275.4A patent/EP2836590A4/en not_active Ceased
- 2013-04-11 EA EA201491666A patent/EA032480B1/ru not_active IP Right Cessation
- 2013-04-11 CA CA2869675A patent/CA2869675C/en active Active
- 2013-04-11 BR BR112014025251-3A patent/BR112014025251B1/pt not_active IP Right Cessation
- 2013-04-11 AU AU2013245917A patent/AU2013245917A1/en not_active Abandoned
-
2014
- 2014-09-29 IL IL234886A patent/IL234886A/en active IP Right Grant
- 2014-10-10 PH PH12014502286A patent/PH12014502286B1/en unknown
-
2017
- 2017-02-06 IL IL250473A patent/IL250473A0/en unknown
- 2017-12-28 JP JP2017253312A patent/JP6535727B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-08 AU AU2018200930A patent/AU2018200930A1/en not_active Abandoned
- 2018-11-30 US US16/206,747 patent/US20190167676A1/en not_active Abandoned
-
2019
- 2019-11-22 AU AU2019268177A patent/AU2019268177A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014025251B1 (pt) | 2021-03-02 |
| HK1206389A1 (en) | 2016-01-08 |
| PH12014502286A1 (en) | 2014-12-15 |
| JP6535727B2 (ja) | 2019-06-26 |
| JP2015516392A (ja) | 2015-06-11 |
| CA2869675C (en) | 2022-06-14 |
| MX2014012179A (es) | 2015-07-14 |
| AU2013245917A1 (en) | 2014-10-23 |
| US20190167676A1 (en) | 2019-06-06 |
| IL250473A0 (en) | 2017-03-30 |
| PH12014502286B1 (en) | 2014-12-15 |
| CA2869675A1 (en) | 2013-10-17 |
| AU2018200930A1 (en) | 2018-03-01 |
| KR102163931B1 (ko) | 2020-10-12 |
| CN104395458A (zh) | 2015-03-04 |
| KR20160046694A (ko) | 2016-04-29 |
| SG11201406359TA (en) | 2014-11-27 |
| WO2013155262A3 (en) | 2013-12-27 |
| US20150250784A1 (en) | 2015-09-10 |
| SG10201704166RA (en) | 2017-06-29 |
| AU2019268177A1 (en) | 2019-12-12 |
| EP2836590A4 (en) | 2016-04-13 |
| EA032480B1 (ru) | 2019-06-28 |
| EP2836590A2 (en) | 2015-02-18 |
| WO2013155262A2 (en) | 2013-10-17 |
| IL234886A (en) | 2017-02-28 |
| CN111840294A (zh) | 2020-10-30 |
| EA201491666A1 (ru) | 2015-03-31 |
| JP2018048209A (ja) | 2018-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6352244B2 (ja) | 骨格筋疲労に対する耐性を向上させるための方法 | |
| AU2017272286B2 (en) | Methods for improving diaphragm function | |
| Schmidt et al. | Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia | |
| EP2963037B1 (en) | Novel pyrazole derivative | |
| Patil et al. | Pyridine and its biological activity: a review | |
| JP6660369B2 (ja) | 神経障害を治療する方法 | |
| JP6419294B2 (ja) | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 | |
| CN109662964A (zh) | 用于改善认知功能的方法和组合物 | |
| Hirst et al. | Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist,(R)-N-(2-methyl-(4-indolyl-1-piperazinyl) ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405) | |
| KR20200090198A (ko) | 트로포미오신 수용체 키나제 A(TrkA) 저해제로서의 피리미딘 유도체 | |
| WO2011133858A2 (en) | Compositions, methods of use, and methods of treatment | |
| CN100413539C (zh) | 5-ht4受体拮抗剂在制备治疗电生理心房改型的药物中的应用 | |
| EA041725B1 (ru) | Применение активатора тропонина скелетных мышц | |
| Poonam | SMOOTH MUSCLE RELAXANT ACTIVITY OF A DIHYDROPYRIMIDINE DERIVATIVE 5-ACYL-6-METHYL-4-PHENYL-2-S-ETHYL-1, 4-DIHYDROPYRIMIDINE (BK-VI) ON ISOLATED RAT UTERUS AND RABBIT AORTIC STRIP | |
| HK1261324A1 (en) | Methods for improving diaphragm function | |
| EA040280B1 (ru) | КОНДЕНСИРОВАННЫЕ БИЦИКЛИЧЕСКИЕ СТИМУЛЯТОРЫ sGC | |
| CN101297807A (zh) | 5-ht4受体拮抗剂在预防或治疗某些心血管疾病中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160411 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160411 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20160705 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160705 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161220 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170316 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170517 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170620 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170828 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180126 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180424 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180508 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180524 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180606 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6352244 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |